Dr Marat Fudim (Duke University, US) presented the results of the BMAD Trial. BMAD was conducted with ZOLL HFMS (Heart Failure Management System), the first and only patch-based pulmonary fluid monitor. The prospective study demonstrated remarkable outcomes, revealing a significant 38% relative reduction in the risk of hospital readmissions within 90 days post discharge and NNT of 14.3. By continuously monitoring vital parameters like thoracic fluid, early signs of deteriorating health could be detected.